Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 2
1(100.0%)
1Total
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT06895746Active Not Recruiting

Multi-omics Study in Citrin Deficiency

Role: collaborator

NCT05879653Phase 2Recruiting

Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)

Role: collaborator

NCT07067723Enrolling By Invitation

Epidemiological and Clinical Characteristics of Human Mpox Outbreak in Equateur Province in the Democratic Republic of Congo (Part2)

Role: lead

NCT07055867Enrolling By Invitation

Epidemiological and Clinical Characteristics of Mpox Outbreak in Equateur, the DR Congo (Part1)

Role: lead

NCT06984705Enrolling By Invitation

Epidemiological and Clinical Characteristics of Human Mpox Outbreak in Equateur Province in the Democratic Republic of Congo (Part3)

Role: lead

NCT06432543Recruiting

Polyethylene Wear Particle Analysis of THA

Role: lead

NCT06426641Active Not Recruiting

Polyethylene Wear Particle Analysis of TKA

Role: lead

NCT06694012Recruiting

Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2

Role: lead

All 8 trials loaded